Single Dose Study of MK-6482 in Healthy Japanese Female Participants

A single-dose clinical study to evaluate the pharmacokinetics of belzutifan (MK-6482) in healthy Japanese female participants

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031220024

Enrollment

Registered

2022-04-16

Start date

2022-04-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Cell Carcinoma

Interventions

- Palens A and C Single dose of MK-6482 80 mg will be administerd. - Palens B and D Single dose of MK-6482 120 mg will be administerd.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Healthy female participants of nonchildbearing potential between the ages of 45 and 64 years

Exclusion criteria

Exclusion criteria: Has a history of clinically significant abnormalities or diseases

Design outcomes

Primary

Measure	Time frame
pharmacokinetics (Cmax, Tmax, AUC0-last, AUC0-inf, CL/F, Vz/F and t1/2)	—

Secondary

Measure	Time frame
Safety (Adverse events)	—

Contacts

Public Contactinquiry mailbox MSDJRCT

MSD K.K.

msdjrct@msd.com+81-3-6272-1957

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026